# A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

> **NCT04332874** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Sarcoma
- Myxofibrosarcoma
- Undifferentiated Pleomorphic Sarcoma
- Alveolar Soft Part Sarcoma

## Interventions

- **PROCEDURE:** Isolated Limb Infusion
- **DRUG:** Pembrolizumab
- **DRUG:** infusion of melphalan and dactinomycin

## Key facts

- **NCT ID:** NCT04332874
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-04-01
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04332874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04332874, "A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04332874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*